{
    "nctId": "NCT06339658",
    "briefTitle": "ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy",
    "officialTitle": "ICG vs Blue Patent as a Tracer in the Performance of TAD in Patients With cN1 Breast Carcinoma After Neoadjuvant Chemotherapy",
    "overallStatus": "RECRUITING",
    "conditions": "Breast Cancer, Axillary Metastases",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 43,
    "primaryOutcomeMeasure": "Detection rate of sentinel lymph node",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Breast cancer cN+ patients who undergo neadjuvant treatment.\n\nExclusion Criteria:\n\n* Patients in whom there is a contraindication for the use of ICG.\n* Patients in whom there is evidence of progression of the disease after neoadjuvant treatment.",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}